Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AEB1102
Co-ArgI-PEG modified human arginase I · 3 trials · 4 indications
The dose level at which no more than 1/6 patients experiences dose-limiting toxicity
Includes significant changes in hematology, chemistry and coagulation laboratory studies as well as in physical exam and vital signs
| Arm | Type | Description |
|---|---|---|
| AEB1102 | EXPERIMENTAL | Each patient may receive AEB1102 administered IV for up to approximately 4 years. |
| AEB1102 (Co-ArgI-PEG) administered via IV weekly. | EXPERIMENTAL | Co-ArgI-PEG modified human arginase I |
| Name | Type | Description |
|---|---|---|
| AEB1102 | DRUG | modified human arginase I |
| Co-ArgI-PEG modified human arginase I | DRUG | - |
Inclusion Criteria: 1. Complete treatment in Study CAEB1102-101A without experiencing any clinically significant adverse event or other unmanageable drug toxicity that would preclude continued dosing 2. Confirmation by the Investigator and the Sponsor determine that it is acceptable for the patient...
Co-ArgI-PEG modified human arginase I is an investigational small molecule being developed for the treatment of Acute Myeloid Leukemia (AML). It is currently in Phase 2 clinical development and has been studied in patients with AML or Myelodysplastic Syndrome.
Co-ArgI-PEG modified human arginase I is being developed by Spyre Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol SYRE.
Co-ArgI-PEG modified human arginase I is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed.
Co-ArgI-PEG modified human arginase I has been studied in a completed Phase 2 trial with the identifier NCT02732184. This trial was a multiple dose, dose escalation study in patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome, enrolling 29 participants in the United States and Canada.
Yes, Co-ArgI-PEG modified human arginase I is also known as AEB1102. The clinical trial NCT02732184, which evaluated this drug, was titled 'A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS'.